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MESSAGE FROM THE DIRECTOR
For the past 23 years,
our major focus has been
cancer immunotherapy
– the hypothesis that the
immune system can be
activated to recognize
and kill cancer cells.
Immunotherapy is not a new
concept. It has been the subject of
investigation for more than 100 years.
There has always been a strong
Walter J. Urba, M.D., Ph.D.
scientific rationale for immunotherapy,
Member, director and endowed
but until recently there was little
chair of Cancer Research
evidence of clinical benefit. Tumor
regressions were so uncommon that, when we started 23 years
ago, the idea that physicians would be able to harness the body’s
immune system to fight cancer was met with skepticism.
Nevertheless, we believed in the power of the immune system and
refused to abandon what we thought was a promising strategy.
With the support of Providence Health & Services, philanthropists,
public and private grants, and industry partners, we built a great
team and continued to learn more about the immune system
and cancer biology. Armed with this knowledge, we were able to
move our innovations from the laboratory to the patient bedside.
The best example of our novel approach is the OX40-based
translational research led by Andrew D. Weinberg, Ph.D., (page
25) and Brendan D. Curti, M.D. (page 15). The OX40 discovery
research performed at our institute was fueled by local

philanthropy, which allowed us to initiate the first-in-human
OX40 trial at Providence Cancer Center, and led to the formation
of the biotechnology company, AgonOx. Providence licensed the
technology to AgonOx, who sublicensed OX40 to one of the
largest pharmaceutical companies in the world. What began as a
philanthropy-driven 30-patient trial in a single hospital in Portland,
Ore. is now being tested in hundreds of patients in multiple cancer
centers around the world.
We are also proud of our contribution to the development of
ipilimumab – the first immunotherapy drug to improve survival
in patients with advanced melanoma. I was honored to serve
as the principal investigator for the international clinical trial that
led to ipilimumab’s FDA approval in 2011, distinguishing the Earle
A. Chiles Research Institute as a leader in cancer immunotherapy.
In the past 10 years, we have witnessed more progress in
cancer care than in the previous 100 years. When we began,
immunotherapy was the focus of only a handful of centers.
Now it is a major program in every cancer center in the United
States and a top priority in every major drug company. There is no
denying that this is a very exciting time in cancer research. However,
despite the significant progress that has been made, substantial
challenges remain because only a minority of patients with
advanced cancer benefit from current therapy.
Every advance in the treatment of cancer is the result of our
investment in research, the teams of scientists and physicians
attempting new approaches and the incredibly brave patients who
volunteer to help move us forward. We are grateful for our many
supporters who have partnered with us, and we invite you to help
us acheive our goal of increasing the number of cancer survivors
through immunotherapy. Together, we can finish cancer.
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FACTS & FIGURES
Investigators & Personnel

Grant Funding, Sponsored
Research & Philanthropy
n

Faculty
Members:
n Clinical
Researchers:
n Lab
Researchers:
n

18
32
46

		 in federal, private and
		 sponsored research funding
n

		
		
		
		

Institute Publications

n

n

Abstracts:

56

Providence Foundations
Center of Hope Campaign 		
raised over
		
for cancer research, including
a gift of $5.5 million

Providence Guest 		
		House opened to patients 		
n

		 and their families through 		
		 philanthropic support

Journal
Articles:

44

$3.4 million annually

n

Book
Chapters:

8

Clinical Trials
n

214 cancer clinical trials

		 open for enrollment,
		including
therapeutic 		
		 trials and 51 Phase I trials
n

total enrollments

Memberships & Collaborations
Bristol Myers-Squibb
		 International 					
		 Immuno-Oncology Network
n

NCI Cancer Immunotherapy 		
		 Trials Network
n

NCI Community Oncology 		
		 Research Program
n

Partnership with MedImmune /
		 AstraZeneca for the clinical
		 development of anti-OX40
n
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NEW & NOTEWORTHY
New Faculty Appointments

Noteworthy Studies & Publications

Kristina H. Young, M.D., Ph.D., and David B. Page, M.D.,
are the two newest physician researchers to join
the Earle A. Chiles Research Institute, and both have
received national recognition. In 2015, they were
among 58 recipients worldwide to be honored with a
Young Investigator Award from the American Society
of Clinical Oncology.

In collaboration with Dung Le, M.D., of Johns Hopkins University,
Todd S. Crocenzi, M.D., was co-investigator on a Phase II study
of PD-1 inhibition in patients with metastatic colorectal cancer.
This landmark study showed that anti-PD-1 was effective in
this subset of patients with advanced colon cancer and defects
in mechanisms of DNA repair. This research helped make the
important correlation between mutational burden and efficacy
of immunotherapy (N Engl J Med. 2015; 372(26):2509).
Read more about Dr. Crocenzi on page 14.

Dr. Young is a radiation oncologist
with a laboratory research focus on
the tumor microenvironment. She
completed her medical education,
residency and doctoral degree in
cellular and developmental biology
at Oregon Health & Science
University, and completed a
Dr. Kristina Young, Dr. Walter
Holman Research Pathway
Urba and Dr. David Page with
Fellowship in the investigation
2015 ASCO Young Investigator
of radiation oncology and basic
Award plaques.
science at the Earle A. Chiles
Research Institute. Read more about Dr. Young on page 26.

Bernard A. Fox, Ph.D, with Carlo B. Bifulco, M.D., led an
international task force evaluating the prognostic value of
the immune score in patients with colorectal cancer. With the
aid of his graduate student, Zipei Feng, multispectral imaging
was used to predict the ability to culture tumor-infiltrating
lymphocytes and the results were presented at major scientific
conferences. Learn more about Dr. Fox on page 16 and
Dr. Bifulco on page 11.

Dr. Page is a medical oncologist specializing in new immunotherapies
for women with breast cancer. After completing his medical
education at Northwestern University Feinberg School of Medicine
and residency at New York Presbyterian Hospital / Columbia
University Medical Center, he completed a medical oncology
fellowship at Memorial Sloan Kettering Cancer Center. Read
more about Dr. Page on page 22.

Brendan D. Curti, M.D., was co-author on the seminal
publication Talimogene Laherparepvec Improves Durable
Response Rate in Patients with Advanced Melanoma, which
led to FDA approval of this innovative oncolytic therapy in
October 2015 (J Clin Oncol. 2015; 33(25):2780). Read more
about Dr. Curti on page. 15.
Rachel E. Sanborn, M.D., served as the Providence Cancer
Center site principal investigator for the clinical trial testing
anti-PD-1(nivolumab) in patients with advanced squamous
non-small cell lung cancer. Following successful trial results,
nivolumab received FDA approval in March 2015, earlier than
… continued
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anticipated, culminating in the first immunotherapy drug
approval for lung cancer. Later in October, the FDA expanded
approval of nivolumab to include previously treated patients
with advanced non-squamous non-small cell lung cancer.
Read more about Dr. Sanborn on page 24.
Preclinical work from the laboratory of William L. Redmond,
Ph.D., has shown the benefit of combining checkpoint
inhibitors, such as anti-CTLA-4 or anti-PD-1, with a galectin-3
inhibitor (GR-MD-02). This led to two translational clinical
trials testing the galectin inhibitor in combination with
checkpoint inhibitors, supported in part by an R21 grant
award from the National Cancer Institute. Read more about
Dr. Redmond on page 23.

Harder Family Endowed Chair in Cancer Research
bestowed on Bernard A. Fox, Ph.D.
On March 5, 2015, family, friends, colleagues and supporters
joined Dr. Bernard Fox in Palm Desert, Calif., for a celebratory
reception in recognition of his contributions to immunotherapy
and global efforts to cure cancer. Presented with the Harder Family
Endowed Chair in Cancer Research by the Providence Portland
Medical Foundation, Dr. Fox received messages of support and
congratulation, including the following selected remarks:
“I’ve known Bernie and supported his research efforts for
20 years. He’s been a key to the growth of the Earle A. Chiles
Research Institute. He’s made me and the Chiles Foundation
proud. And the most exciting part of all this is the fact that he
has so much more to offer us all. As the holder of the Harder
Chair, he will continue with new discoveries. He will continue to

Dr. Walter Urba, Caryn Urba, Steve Harder, Cindy Harder, Lori Fox and
Dr. Bernard Fox

publish his findings. He will continue on the path to cure cancer.”
- Earle M. Chiles & The Chiles Foundation
“Bernie is a world-recognized scientist who is frequently called
upon by granting agencies, such as the NIH and FDA, academic
institutions, biotechnology and pharmaceutical companies to
provide expert opinion and serve as a subject matter expert in the
immunotherapy of cancer.” – Raj K. Puri, M.D., Ph.D., director,
Division of Cellular and Gene Therapies, Center for Biologics
Evaluation and Research, U.S. Food & Drug Administration
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“Thank you, Bernie, for leading me and others along the path to
finding a cure for cancer. Congratulations to you as you receive
this prestigious honor.” – Tara Withington, executive director,
Society for Immunotherapy of Cancer.
“Your vision of cancer immunology and immunotherapy, and your
passion and tireless efforts at realizing its success in our lifetime
(who would have ever thought we would witness it from our days
together at the NCI so many years ago!), will forever set apart
the Earle A. Chiles Research Institute as one of the leaders in
our field.” – James J. Mulé, Ph.D., associate center director for
Translational Science, Moffitt Cancer Center.
Learn more about Dr. Fox on page 16.

Your vision of cancer immunology and immunotherapy, and your passion
and tireless efforts at realizing its success in our lifetime...will forever set
apart the Earle A. Chiles Research Institute as one of the leaders
in our field.
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A PATIENT’S JOURNEY
Steve Smith had few options for surviving stage IV colon
cancer, but he entered a Phase I trial at Providence
Cancer Center and gained a new lease on life.
Steve Smith, 63, sits by the fire in the main floor of Providence
Guest House after flying in from Montana the night before and
receiving his infusions of varlilumab and nivolumab that morning.
He quips, “I already had an expiration date.”
It’s an amusing joke for the 29-year career salesman in grocery
products for Proctor & Gamble. He’s in a good mood and
explains why.
In February 2014, shortly after retiring and moving with his wife
back to his boyhood home in Great Falls, Smith was diagnosed
with stage IV colon cancer with liver metastases. He underwent
chemotherapy for a year, a colectomy, seven tumor resections and
removal of 24 lymph nodes. His cancer was stable for six months
and then progressed.
With limited options in Montana, Smith and his oncologist began
searching the Web and determined an immunotherapy trial
offered the best hope. They found clinical trials that looked
promising in Seattle, Phoenix and Minneapolis, among other
cities, but decided on Portland because of the pioneering work
performed at Providence Cancer Center and for its proximity
to Vancouver, Wash., where Smith lived for much of his
working career.

Screening Period
In April 2015, Smith visited Providence Cancer Center for a
consultation with Todd S. Crocenzi, M.D., to see if he qualified for

a Phase I/II trial combining
two immunotherapy agents,
varlilumab and nivolumab,
in patients with advanced
cancers. The screening
included urine testing,
electrocardiogram,
chest X-ray, tumor biopsy,
CT scans of his chest,
abdomen and pelvis,
and brain and blood draws
to verify the absence of
complicating factors.
A screen for biomarkers
such as the non-mutated
KRAS gene provided data
to help investigators
determine whether Smith
might respond to the drugs.

Steve Smith, a clinical trial patient of
Dr. Todd Crocenzi, stays at Providence
Guest House when receiving treatment.
Located within walking distance to
Providence Cancer Center, Providence
Guest House opened in August 2015
through generous philanthropic support
for out-of-town patients and families.

“Fortunately for me, I met
the requirements. As a
cancer patient, you have to
investigate what’s out there or miss an opportunity,” he says.

When Smith enrolled in the trial, he was among a small cohort of
patients who have received a mid-range dose of medication. By
2020, the target end date of the trial, approximately 190 patients
are expected to be enrolled at up to 15 sites in the country. This is
the first time varlilumab and nivolumab have been tested together
in humans.
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Home Away From Home
While the costs of the drugs are covered for Smith, he figures he’d
spend about $30,000 on travel. Early on, no stranger to a lot of
miles on the road in his job, Smith didn’t mind driving himself to
his infusions every two weeks – a 700 mile trip. He says he used
the time to turn on the music and let it all go. “Once I started to
feel the results, a lot of my anxiety was taken care of,” he says.
Being able to stay at the Providence Guest House close to the
hospital has made a huge difference to Smith. He doesn’t feel
as transient as he did hopping around from one budget hotel to
another like he and his wife did earlier in the trial. He uses some
of his free time seeing a brother who lives in Vancouver.
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While reading the long list of possible side effects was intimidating,
Smith shrugs off what he has experienced as mild – irritability at the
site of his chest infusion port, joint pain and diarrhea. “You work it
out when it’s all compared to staying alive,” he says.
Also, there has been the improvement in his quality of life. Smith
has been enjoying spending time with his family, which includes
nine grandchildren and 12 great-grandchildren. Among hobbies
he’s taken up is panning for gold.
“I’m healthy enough to enjoy retirement,” he says.
Feature courtesy of Providence inScope.

“We are very pleased that we could offer Mr. Smith a therapeutic
trial that was not available in his home state, and that he has
shown a positive response to treatment. We are also grateful that
he and his family are able to stay at the Providence Guest House
during his treatment,” says Dr. Crocenzi.

Results
At the end of June 2015, two months after his screening visit, a
CAT scan showed a 30 percent reduction in Smith’s tumors; by
August, 43 percent; October, 60 percent; December, 75 percent;
and at the end February 2016, Smith’s tumors had reduced by
84 percent.
“I could be totally clear,” Smith says. “I’m not the only one who’s
shaking his head.”

Dr. Todd Crocenzi, right, and his patient, Steve Smith, review Smith’s
CT scan showing tumor regression in response to the combination
varlilumab and nivolumab Phase I/II clinical trial.
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R. Bryan Bell, M.D.,
D.D.S., FACS
Assistant member and medical director,
Providence Oral, Head & Neck Cancer
Program and Clinic
Head and Neck Oncologic Surgery
Dr. Bell’s research interest is in the characterization and
manipulation of the tumor microenvironment in head
and neck cancer. He seeks to develop novel clinical trials
and treatment strategies to stimulate pre-surgical immune
responses in patients with head and neck squamous
cell carcinoma.
Since joining Providence Cancer Center in 2010, Dr. Bryan Bell
has been instrumental in expanding clinical research for patients
with oral, head and neck cancer. Working closely with Rom S.
Leidner, M.D., the portfolio of clinical trials has grown from one
cooperative group trial in 2010 to more than 25 investigatorinitiated, industry-funded and cooperative group trials in 2015.
Dr. Bell serves as the principal investigator on a Phase Ib
investigator-initiated trial of anti-OX40 prior to surgical resection,
as well as an industry-sponsored Phase II trial of IRX-2, which
contains interleukin-2 and various cytokines, administered at
pre- and post-surgical resection. Nationally, Dr. Bell is among the
highest accruing surgeons in a Phase II cooperative group trial
(ECOG 3311) investigating transoral robotic surgery in head
and neck squamous cell carcinoma (HNSCC). In August 2015,
Drs. Bell and Leidner hosted the inaugural New Horizons in
Immunotherapy for Head and Neck Cancer Symposium held
in Newberg, Ore., bringing together leading investigators in
HNSCC immunotherapy.
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In collaboration with the Integrated Therapies Laboratory led by
Marka R. Crittenden, M.D., Ph.D., and Michael J. Gough, Ph.D.,
Dr. Bell seeks to develop a perioperative immunotherapy strategy
to clear residual cancer cells in the surgical site without impacting
normal tissues, anatomic structures or wound healing. “Such
an intervention may also increase the number of patients eligible
for surgical resection, since patients whose tumors have invaded
critical structures may become eligible for surgery if we are able
to eliminate remaining cancer cells,” says Dr. Bell.
Dr. Bell has also engaged in a next generation immunoprofiling
collaboration with Bernard A. Fox, Ph.D., whose laboratory
has established a head and neck cancer tumor bank and
cryopreserved more than 250 tissue samples from Dr. Bell’s
patients. Multispectral imaging analyses of tumors from a cohort
of patients with HNSCC has resulted in the development of a
potential prognostic biomarker for oral cancer that may be
used in the future to direct conventional treatment as well as
immunotherapy.
Another intramural collaboration includes Dr. Bell’s partnership
with Andrew D. Weinberg, Ph.D., to examine the expression
of immune modulatory proteins, OX40, PD-1, and CTLA-4, in
HNSCC and to see whether these proteins could be targeted
alone or in combination for future clinical trials. Further studies
are centered on evaluating the primary tumor, metastatic
and non-metastatic draining lymph nodes to identify novel
immunotherapy targets, biomarkers of response, and how
to best use immunotherapy combinations with the goal of
translating their findings into innovative clinical trials.
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Carlo B. Bifulco, M.D.
Member and director, Translational
Molecular Pathology and Informatics
Anatomic and Molecular Pathology
As a pathologist with subspecialty
training and expertise in molecular
genetic pathology and hemato-pathology, Dr. Bifulco
serves as director of the Molecular Pathology Core at
the Earle A. Chiles Research Institute. He also serves as
co-leader of the Biospecimen Core for the Pacific Cancer
Research Consortium, a community site of the NCI
Community Oncology Research Program.
“Medicine is undergoing a major shift toward personalized
health care, a model in which preventive and therapeutic
practices are custom designed for each patient’s specific needs,”
says Dr. Carlo Bifulco. “For cancer, personalized treatment is
made possible by rapid and dramatic advances in DNA sequencing,
which enables us to decode tumor genomes, and by new drugs
that selectively target cells with damaged or mutated genes.
These developments allow us to match drugs to patients with
specific tumors, resulting in better outcomes, less toxicity and
lower costs.”
The Molecular Pathology Core plays an important role in
detecting tumor-driver mutations and tumor pathways that
will respond well to certain drugs. It performs or coordinates
tests for several molecular targets in multiple tumor types,
including breast, colon, lung and hematologic malignancies.

Test results are routinely incorporated into diagnostic pathology
reports. “Now we’re preparing for the next leap forward in
personalized care,” says Dr. Bifulco. “We’re transitioning from
single gene mutation testing – that is, focusing on one gene
at a time for specific targetable mutations – to mapping and
decoding whole genomes. By comparing the patient’s normal
DNA to the tumor DNA, we can identify all the potentially
actionable mutations. This allows for more targeted,
personalized treatment.”
At Providence Cancer Center, this process will be developed
in stages through a multiphase approach. “First we’ll focus on
characterizing cancers through next-generation sequencing of
gene groups currently associated with specific tumor types.
Later, as the technology and data interpretation become
standardized and increasingly robust, we’ll extend this approach
to the whole exome – the part of the genome most frequently
altered in tumor-driving mutations. The ultimate goal is complete
genetic profiling of tumors with the sequencing of whole tumor
genomes,” says Dr. Bifulco.
This shift in cancer diagnostics and treatment approach will
result in better and more affordable diagnostics and, most
importantly, in improved clinical outcomes. Because there is an
important role for personalized immunotherapy to complement
the advancements in medical genomics and bioinformatics,
Dr. Bifulco’s team is developing tests to characterize a patient’s
immune response to a tumor. “We’re hopeful that this
immunoprofiling approach will allow for further personalized
use of immunotherapeutic agents in cancer treatment.”
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Alison K. Conlin, M.D.,
MPH
Associate member and medical director,
Providence Breast Cancer Program
and High-Risk Breast Clinic
Medical Oncology
As a medical oncologist with training in population health
and health outcomes, Dr. Conlin specializes in breast cancer
clinical research as well as breast cancer risk evaluation,
screening, and clinical and lifestyle interventions.
Since her arrival at Providence Cancer Center in 2008, Dr. Alison
Conlin has been an active clinical investigator. She serves as a
member of the Alliance for Breast Cancer Committee. She is a
member of the Southwest Oncology Group Breast Committee
and Breast Cancer Working Group, in which she founded and
co-chairs the Brain Metastasis Working Group.
“Currently, I am on the advisory board of the Providence Breast
Health Registry – a database of patients’ screening, diagnostic,
treatment, and follow-up information,” says Dr. Conlin.
“Additionally, I am the medical director of our high-risk breast
clinic where we evaluate women for their breast cancer risk
and counsel them to consider medications to reduce risk, such
as tamoxifen, raloxifene, or exemestane, appropriate screening
and testing practices, and lifestyle modifications that may
reduce risk of future breast cancer.”
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In late 2014, Dr. Conlin became the co-principal investigator for
the Providence Portland Medical Center site of the Pacific Cancer
Research Consortium (PCRC), a community site of the NCI
Community Oncology Research Program (NCORP). Comprising
three major community cancer centers in the Western United
States, PCRC includes Swedish Cancer Institute in Seattle,
Mountain States Tumor Institute in Boise, and Providence
Portland Medical Center, home to Providence Cancer Center
and the Earle A. Chiles Research Institute. Along with their
sub-components and 27 other participating components across
Alaska, Washington, Oregon, Idaho, and California, PCRCNCORP is a consortium of 48 sites designed to conduct multi-site
cancer clinical trials and cancer care delivery research through a
5-year grant award from the NCI.
Dr. Conlin is the leader of the PCRC Research Base Core which
oversees the selection of PCRC cooperative group trials and
represents PCRC to the National Clinical Trials Network Research
Base. “The function of the PCRC Research Base Core is to ensure
that we screen and select appropriate protocols for our PCRC
sites and that we achieve accrual requirements,” says Dr. Conlin.
“This is done through engaging and capitalizing on our
investigators’ disease-specific expertise to review and select
clinical trials from the participating research base portfolios.”
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Marka R. Crittenden, M.D.,
Ph.D.
Assistant member, Integrated Therapies
Laboratory
Director, Translational Radiation Research
Radiation Oncology
As a physician scientist trained in both radiation oncology
and immunology, Dr. Marka Crittenden has a strong interest
in the development of immunotherapy approaches for the
treatment of cancer.
“In my role as director of Translational Radiation Research, I am
involved in multiple investigator-initiated Phase I and Phase II
clinical studies combining immunotherapy with radiation therapy
in melanoma, breast cancer, pancreatic and prostate cancer,”
says Dr. Marka Crittenden. “I also co-lead with Michael J.
Gough, Ph.D., the Integrated Therapies Laboratory which
studies the integration of immunotherapy approaches targeting
the immune environment within the tumor and conventional
therapies such as chemotherapy and radiation.” Learn more
about the Integrated Therapies Laboratory on page 18.
In 2015, Dr. Crittenden contributed to numerous publications
with intramural and extramural collaborators. She co-authored
six journal articles and seven abstracts, including a first author
publication entitled Current Clinical Trials Testing Combinations
of Immunotherapy and Radiation (Semin Radiat Oncol.
2015;25(1):54). At the 2015 annual meeting of the American
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Society of Clinical Oncology, she gave poster presentations on
a Phase I/II study of stereotactic body radiation therapy in
combination with a monoclonal antibody to OX40 in patients
with metastatic breast cancer and a Phase I study of safety and
immunogenicity of a Listeria monocytogenes vaccine, ADU-623,
in patients with WHO grade III/IV astrocytomas. She served as
institutional principal investigator on clinical trials for patients
with glioblastoma and other tumor types, including a first-inhuman study of a monoclonal antibody to PD-1 administered
alone and in combination with other anti-cancer therapies in
patients with advanced malignancies.
Additionally, Dr. Crittenden served as an expert discussant for the
Immunotherapy and Radiation Therapy session of the American
Society of Therapeutic Radiation Oncology 2015 annual meeting
in San Antonio, and co-chair of the Immune Therapy and Immune
Modulation Workshop at the NRG Oncology Semi-Annual Meeting
in Denver. She attended the 2015 annual meeting of the
American College of Radiation Oncology in Washington, D.C.,
where she presented on “Radiation and Immunotherapy: A
Primer,” as well as the 2015 annual meeting of the Radiation
Research Society in Weston, Fla., where she presented on
myeloid response to radiation therapy. Dr. Crittenden was also
an active participant in the Radiation and Immune Modulation
Working Group and Lung Cancer Working Group of the
National Cancer Institute and engaged in collaborations with
UC Davis, Sanford Health and Baylor College of Medicine.

13

14

FACTS &
FIGURES

NEW &
NOTEWORTHY

A PATIENT’S
JOURNEY

FACULTY
MEMBERS

CORE
FACILITIES

EDUCATION &
TRAINING

EVENTS &
ENGAGEMENT

FRANZ LEADERSHIP
CABINET

SELECT
PUBLICATIONS

Todd S. Crocenzi, M.D.
Associate member and director,
Gastrointestinal Oncology Research
Medical Oncology
As a medical oncologist with a strong
interest in the immunologic aspects of
cancer biology, Dr. Crocenzi’s ongoing
professional goal is to develop methods of redirecting
the immune system as a cancer therapeutic.
As an oncology fellow at Dartmouth Hitchcock Medical Center,
Dr. Todd Crocenzi was mentored by Marc Ernstoff, M.D., in the
clinical care of patients with advanced melanoma and renal cell
carcinoma undergoing standard and investigational immunotherapy
regimens. He also gained experience in translational research
and was a co-principal investigator on an institutional grant
which funded a clinical trial of a novel dendritic cell vaccine
for metastatic melanoma and renal cell carcinoma. It was this
training and experience in investigational immunotherapy which
led to Dr. Crocenzi’s directorship of Gastrointestinal Oncology
Research at the Earle A. Chiles Research Institute, where he
seeks to improve immunotherapeutics for patients with
gastrointestinal cancers.
“As a physician scientist developing novel cancer therapy, I believe
immunotherapy can integrate with current conventional
therapies to optimize effectiveness. To this end, I designed

and conducted two clinical trials evaluating the safety and
feasibility of chemo-immuno-radiotherapy in patients with locally
advanced or borderline resectable pancreatic cancer. I continue
to work with Michael J. Gough, Ph.D., and Marka R. Crittenden,
M.D., Ph.D, to analyze blood and tissue samples from these
patients to formulate other translational research projects in
pancreatic, liver and colorectal cancer,” says Dr. Crocenzi.
Dr. Crocenzi has collaborated with Duke University on a
multi-institutional clinical trial to explore a multi-peptide, viral
vector delivered vaccine in patients with resected, metastatic
colorectal cancer. Most recently, Dr. Crocenzi collaborated with
Dung Le, M.D., of Johns Hopkins University in the clinical trial
demonstrating the efficacy of PD-1 inhibition in patients with
metastatic colorectal cancer and mismatch repair deficiency (N Engl
J Med. 2015; 372(26):2509). “Dr. Le and I were also awarded a
PANCAN-AACR Research Acceleration Network Grant, a
$1 million award to support our ongoing clinical trial exploring
a prime-boost vaccination strategy in combination with
anti-PD-1 antibody for second line treatment of metastatic
pancreatic adenocarcinoma,” says Dr. Crocenzi.
Dr. Crocenzi is an active investigator on several other
investigator-initiated clinical trials combining immunotherapy,
chemotherapy and radiation therapy as well as multi-center
studies through the Cancer Immunotherapy Trials Network
and the cooperative group system of the NCI.
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Brendan D. Curti, M.D.
Member and director, Genitourinary
Oncology Research
Director, Cytokine and Adoptive
Immunotherapy Program
Co-director, Providence Melanoma
Program
Medical Oncology
Dr. Curti is a principle investigator on numerous translational
clinical trials and a recognized leader in melanoma,
genitourinary and interleukin-2 (IL-2) immunotherapy.
Dr. Brendan Curti served as the principal investigator on the firstin-human OX40 study that was performed at Providence Cancer
Center. Based on the promising results of the Phase 1 trial, new
OX40 agonists and combinations are being investigated in the clinic
in conjunction with collaborators at MedImmune, which acquired
the rights to develop OX40 agonists. This includes several in-house
studies testing the immunological effects in the tumor specimens of
pre-operative administration of anti-OX40 in patients with advanced
oral, head and neck cancer, and in patients with liver metastases
from colorectal cancer.
Intratumoral therapy for melanoma has been a longstanding clinical
research interest of Dr. Curti’s. Providence Cancer Center enrolled
the first patient on the Phase III talimogene laherparepvec trial that
was the basis for its FDA approval (J Clin Oncol 2015, 33(25):2780).
Dr. Curti is an active collaborator on clinical research studies investigating another oncolytic virus, CAVATAK (Coxsackie Virus CVA-21).
Presentations of this research were given at the 2015 annual
meetings of the American Society of Clinical Oncology and
American Association for Cancer Research. “Based on pre-clinical

data showing synergy with anti-CTLA-4, I authored a clinical trial
studying the combination of CAVATAK and ipilimumab in patients
with advanced melanoma and a subcutaneous melanoma deposit
suitable for intratumoral vaccination,” says Dr. Curti. Four of the first
five patients have achieved a partial regression of disease. Detailed
analysis of immune parameters including immunoscore is being
performed. Collaborators include the John Wayne Cancer Institute
and the Huntsman Cancer Institute.
Galectins are proteins with immune suppressive properties produced
in excess by many malignancies. William L. Redmond, Ph.D., studied
galectin inhibitors in conjunction with T-cell costimulatory antibodies
and demonstrated enhanced anti-tumor activity in pre-clinical tumor
models. To translate this work to the clinical setting, Dr. Curti authored
two clinical trials, one combining the galectin inhibitor, GR-MD-02,
with the anti-CTLA-4 agent, ipilimumab, and another combining it
with the anti-PD-1 agent, pembrolizumab. Both are first-in-human
studies conducted at Providence Cancer Center. An R21 NIH grant
award for immune monitoring on these trials was funded in 2015.
Dr. Curti’s investigations of stereotactic body radiation therapy (SBRT)
plus IL-2 in collaboration with Marka R. Crittenden, M.D., Ph.D., are
ongoing. The randomized Phase II study in melanoma, which opened
in 2012, is nearing completion. The results are still preliminary;
however, the probability of objective response in patients who
received SBRT plus IL-2 was 30 percent and those receiving
IL-2 monotherapy was approximately 15 percent. Another randomized
Phase II comparison of SBRT plus IL-2 and IL-2 began enrolling in 2015
in patients with advanced renal cancer. A biomarker study of the
immunomodulatory effects of IL-2 in these patients was published
(Immunity 2015, 43(2):240). Other Cytokine Working Group members
will become collaborators on the SBRT plus IL-2 trial in renal cancer
in 2016.
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Bernard A. Fox, Ph.D.
Member, Molecular and Tumor
Immunology Laboratory
Harder Family Endowed Chair in
Cancer Research
Dr. Fox and his laboratory seek to
improve the effectiveness of cancer
immunotherapy. This includes a preclinical effort to develop
strategies to increase efficacy and a clinical effort to translate
these findings into clinical trials for patients with cancer.
“My lab is interested in assessing the immune infiltrate that
exists within the tumor microenvironment, also known as
immunoscore, and how we might increase the number and
augment the function of immune cells in that environment
through various immunotherapeutic strategies. Patients with a
positive immunoscore have fared well on checkpoint inhibitors
such as anti-PD-1, but patients with a negative immunoscore
require other immunotherapeutic modalities to increase their
immunoscore, and this is a major focus of my research,”
says Dr. Bernard Fox. The immunoscore research by the Fox
Laboratory has led to a biotechnology collaboration with
PerkinElmer enabling the use of multispectral imaging to
assess five to eight markers on a single tumor section. This has
allowed a greater understanding of cell types, functionality,
and cell-to-cell interactions within the tumor microenvironment.
This work was performed with samples from both pre-clinical
models and samples from clinical trials, and was presented at
the American Association of Immunologists and the Society for
Immunotherapy of Cancer (SITC) 2015 annual meetings.

The future of immuno-oncology lies in combination immunotherapies, and Dr. Fox’s laboratory is studying the impact of
combining various reagents to improve anti-tumor efficacy.
“We have found that the sequence of how antibodies for OX40
and PD-1 are administered is important in determining whether
combination treatment is effective,” says Dr. Fox. “We have
partnered with a major pharmaceutical company to examine
novel reagents targeting immune function, and our research
was cited as part of the technical brochure for FDA approval of
the first-in-human clinical trial of anti-VISTA. Our hope is that
this combination approach will lead to more effective cancer
therapies for patients.”
An additional focus of the laboratory is assessing antibody
responses both as an effector function as well as surrogates of
T-cell immunity in both human and murine systems. “Previously,
we observed in a clinical trial of combination immunotherapy for
men with advanced prostate cancer, those who had increased
PSA doubling time had increased number of strong antibody
responses to antigens on circulating tumor cells,” says Dr. Fox.
“We extended this research in a pre-clinical model demonstrating
that our autophagosome vaccine, DRibbles, plus poly-IC
produced antibody responses against antigens within the
vaccine.” This work was also presented at the 2015 SITC annual
meeting, where Dr. Fox was honored with a SITC Visionary /
Legacy Award in recognition of his ingenuity and steadfast
commitment to advancing cancer immunotherapy. Earlier in
the year, Dr. Fox was awarded The Harder Family Endowed
Chair in Cancer Research by the Providence Portland Medical
Foundation in honor of his distinguished record of leadership
and scientific contributions (see page 6).
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John E. Godwin, M.D.,
MS
Member and program leader,
Hematologic Malignancies
Medical Oncology
Dr. Godwin’s research interest is in clinical
immunotherapy of hematologic malignancies, also known
as blood cancers. This entails understanding the various
mechanisms of immune resistance and suppression in
hematologic malignancies.
Through intramural and extramural collaborations, Dr. John Godwin
seeks a greater understanding of immune system functionality in
hematologic malignancies for the development of more effective
cancer therapeutics. In 2015, Dr. Godwin’s activities were devoted
to several areas of hematological research. “Firstly, I have brought
about unique investigator-initiated studies,” says Dr. Godwin.
One is a tissue collection protocol for bone marrow samples in
Myelodysplastic Syndromes (MDS) patients, specifically evaluating
the presence of myeloid derived suppressor cells in MDS.
“Secondly, we have enhanced our clinical trial portfolio by opening
several novel immunotherapy trials in hematologic malignancies,”
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says Dr. Godwin. These include the chimeric antigen receptor (CAR)
T cell therapy from Kite Pharma for mantle cell Non-Hodgkin
Lymphoma (NHL) and the bispecific antibody therapy for Acute
Myeloid Leukemia (AML), MGD006. A trial investigating the
anti-CD30 immunoconjugate in combination with anti-PD-1
(nivolumab) through Bristol-Myers Squibb and Seattle Genetics
has also been opened, and activation of a trial of the anti-CD33
immunoconjugate from Seattle Genetics, SGN33, for AML and
MDS is in process. “We are one of only a few sites in the country
working with Kite CAR T cells and the MGD bispecific antibody,”
says Dr. Godwin.
Additionally, Dr. Godwin is responsible for the continued
development of the hematologic malignancies program in the
Providence Oregon Region. “We have an active tumor board that
has increased presentations, and our enrollment in clinical trials in
hematologic malignancies has increased in the past year,” says
Dr. Godwin. In 2015, Providence Health & Services established a
system-wide Clinical Program Group focused on hematologic
malignancies, of which Dr. Godwin is a co-leader. Through this
group, Dr. Godwin has been active in establishing a system-wide
pathology report which includes specific tumor markers in NHL.
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Michael J. Gough, Ph.D.
Assistant member, Integrated Therapies
Laboratory
The Integrated Therapies Laboratory is
a collaborative research effort between
Michael J. Gough, Ph.D., and Marka R.
Crittenden, M.D., Ph.D. It encompasses
their overlapping research interest into the ability of
cytotoxic therapy to provide large-scale cancer cell death
in vivo, while modifying the immune cell profile within
the tumor.
“This year was an important year for the
laboratory,” says Dr. Michael Gough.
“Firstly, we expanded. We acquired a second
post-doctoral fellow and two additional
research associates in 2015. Secondly, our
projects based around the STING sensor have
matured. We have successfully published our
first paper on this topic in Cancer Research,
which also resulted in an image of ours being selected
as cover art for the January 2016 issue,” says Dr. Gough
(Cancer Res. 2016 Jan 1;76(1):50. Epub 2015 Nov 13).
Subsequent manuscripts are in progress and three grant awards
to continue investigation of the STING sensor were received:
a postdoctoral fellowship from the American Cancer Society;
an award from the Oral Maxillofacial Surgery Foundation with
R. Bryan Bell, M.D., D.D.S., to initiate a preclinical surgical model;
and an award from the Heath Foundation to apply findings to
pre-malignant disease.

A collaboration with Victor DeFilippis, Ph.D., at the Vaccine and
Gene Therapy Institute to investigate a collection of novel small
molecule STING ligands is underway. The laboratory’s collaboration
with Jacob Raber, Ph.D., at Oregon Health & Science University
has continued to earn grant awards, most recently resulting in a
prestigious Howard Hughes Medical Institute Medical Research
Fellows Award for a second-year medical student under
Dr. Gough’s mentorship.
The laboratory has developed a strong pipeline of new areas
of investigation. Much interest has been shown in its project
investigating the role of macrophage phagocytic receptors in
the response to radiation therapy. Manuscripts describing one
candidate pathway and findings from the laboratory’s first
clinical trial testing pancreatic cancer patients are in development.
National recognition has brought Dr. Gough invitations to speak
at medical, scientific and industry conferences and meetings.
Presentations were given at Thomas Jefferson University, Rigel
Pharmaceuticals, Bristol Meyers-Squibb, and New Horizons in
Immunotherapy for Head and Neck Cancer Symposium with
additional presentations at universities and conferences planned
in 2016. See page 13 to learn about Dr. Crittenden’s activities.
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Hong-Ming Hu, Ph.D.
Associate member, Cancer
Immunobiology Laboratory
The long-term goal of the Cancer
Immunobiology Laboratory is to
understand how the immune system
senses tumor cells and to develop effective
cancer vaccines and other immunotherapy strategies.
Dr. Hong-Ming Hu leads the Cancer Immunobiology Laboratory
in productive, innovative research with a special interest in
the development of therapeutic cancer vaccines. He is both
knowledgeable and well versed in molecular and cellular
immunology studies and is directly involved in the clinical
translation of ideas and concepts that originate from his
laboratory. “My laboratory investigates how tumor cells,
live or dead, are sensed by the immune system. A better
understanding of how the immune system recognizes tumor
cells will lead to the design of more effective cancer vaccines
and immunotherapy strategies,” says Dr. Hu.
Dr. Hu’s interest in autophagy, the mechanism by which cells
dispose of unnecessary or dysfunctional components, and its
role in regulating antitumor immune responses has spawned
several areas of investigation. “Our research in antigen crosspresentation led to an original finding that cross-presentation of

tumor-associated antigen is regulated by autophagy in tumor
cells. We have also made several new discoveries that uncover
the mechanisms by which autophagy regulates the efficiency
of cross-presentation and antitumor immune responses,” says
Dr. Hu. “Based on these exciting discoveries, we seek to develop
a deeper understanding and clearer picture of how autophagy
regulates antitumor immune response.”
Another major focus of Dr. Hu’s laboratory is the research and
development of DRibble vaccines, a novel therapeutic cancer
vaccine platform based on tumor-derived autophagosomes
developed in collaboration with Bernard A. Fox, Ph.D. DRibbles
have been shown to induce a strong tumor-specific immune
response and mediate tumor regression in several tumor models.
Using pre-clinical models of breast and lung cancer, Dr. Hu’s
laboratory has determined that the effect of a combination of
agonist antibodies against T-cell costimulatory molecules (OX40,
CD27, GITR) and/or immune checkpoint blockade (PD-1 or
PD-L1) could boost T-cell mediated immune responses induced
by vaccination with DRibbles. “We generated preliminary data
showing such combinations are therapeutically more effective
than either vaccine or antibody alone,” says Dr. Hu. “Ongoing
experiments are underway to determine the antitumor effects
and mechanisms of these combinations. Results from these
studies could form the basis for multiple clinical trials.”
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Rom S. Leidner, M.D.
Assistant member and co-director,
Providence Oral, Head and Neck
Cancer Program
Medical Oncology
Dr. Leidner has pioneered the expansion
of immunotherapy in head and neck
cancer, applying knowledge gained from lung cancer and
melanoma studies to patients with head and neck cancer.
The success of immunotherapy in melanoma has inspired many
researchers to test the impact of boosting the immune system
against other cancer types. As a physician scientist with an
interest in head and neck cancer, Dr. Rom Leidner has been at
the leading edge of applying various immunotherapy agents to
head and neck cancer patients, including immune checkpoint
inhibitors, combination therapies, and adoptive transfer of tumor
infiltrating lymphocytes (TIL). Through philanthropic support
from Providence Portland Medical Foundation, Dr. Leidner
treated the first oral squamous cell carcinoma (SCC) patient with
adoptive TIL plus tumor-derived, autophagosome-enriched
DRibbles vaccine (DPV-001). His group was the first to enroll
SCC patients in trials of both pre-operative murine OX40 agonist
(MEDI6469) and pre-operative anti-PD-L1 (durvalumab). “We
ran the first-in-human Phase I trial of a humanized monoclonal
OX40 agonist antibody, MEDI0562, in patients with head and
neck squamous cell carcinoma,” says Dr. Leidner. “We are at
the national forefront in this capability.”
Dr. Leidner authored and presented five abstracts at international
meetings and co-authored two articles in 2015, including a

publication with R. Bryan Bell, M.D., D.D.S., on effective
immunotherapies in oral, head and neck cancer (J Oral Maxillofac
Surg. 2015;73(12 Suppl):S107). Together with Dr. Bell, he
organized the inaugural New Horizons in Immunotherapy for
Head and Neck Cancer Symposium, bringing together leading
investigators in the field of head and neck squamous cell
carcinoma (HNSCC) immunotherapy.
An active member of the Providence Portland Medical Center
Institutional Review Board, Dr. Leidner serves as the site principal
investigator on 10 Phase I/II clinical trials, including a newlyopened investigator-initiated trial using liquid biopsy to analyze
circulating tumor DNA in plasma from head and neck cancer
patients. Another trial testing a human monoclonal anti-PD-1
treatment for cutaneous SCC will begin recruiting patients in
2016. Additional industry-sponsored studies are in development,
testing intra-tumoral modeling directly at the level of cancer cells
and TIL in HNSCC patients.
Dr. Leidner values the collaborative environment of the Earle A.
Chiles Research Institute. Through multiple intramural collaborations,
he has helped build a database of more than 100 samples from
HNSCC patients for the creation of autologous TIL and multiplex
immunohistochemical analyses of immune infiltration in primary
tumors. These tissue libraries have potential as future discovery
platforms for adoptive transfer and aid in predicting patient
responders. Ongoing intramural collaborations will focus on both
human and pre-clinical studies of combination immunotherapies
for head and neck cancer. Dr. Leidner hopes to expand his
clinical research endeavors in glioblastoma, gastroesophageal,
thyroid, salivary, and other rare tumors in the future.
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Philippa H. Newell, M.D.
Assistant member and medical director,
Providence Liver Cancer Clinic
Liver and Pancreas Surgery
Dr. Newell is pursuing new combination
therapies for patients with hepatocellular
carcinoma, the most common type of
primary liver cancer. By combining traditional liver-directed
therapies with immunotherapy, she hopes to provide a
wider range of effective treatment options for this
patient population.
Many patients with hepatocellular carcinoma (HCC) have
underlying chronic liver disease and recurrence rates following
standard treatment are high. Radiofrequency ablation (RFA) for
HCC involves a specialized needle that is placed in the center
of the tumor to destroy tumor cells with high temperature, also
known as thermal ablation. By removing a small piece of the
tumor from the needle, Dr. Philippa Newell can analyze the
molecular pathways that are altered in response to RFA. She has
found an increase in heat shock proteins, which mediate the
cellular response to protein damage and are indicators of cellular
stress. “The big challenge with these molecular approaches is
teasing out the effects of the tumor, compared to the treatments,
when the liver itself is also highly diseased,” says Dr. Newell.
Dr. Newell is principal investigator or co-principal investigator on
multiple clinical trials. She co-authored and presented five posters
at international research conferences in 2015 and was first
author on the article Mulitmodal Treatment of Unresectable
Hepatocellular Carcinoma to Achieve Complete Response
Results in Improved Survival (HPB 2015, 17(5):454).

Dr. Newell is investigating combinations of the immune
checkpoint inhibitor anti-PD-1 plus stereotactic radiation and
RFA in a Phase I/II safety and feasibility trial for HCC patients.
She is also investigating the molecular pathways affected by these
combinations in pre-clinical models of liver cancer with Marka R.
Crittenden, M.D., Ph.D., and Michael J. Gough, Ph.D. Additionally,
Dr. Newell has started a Phase I safety trial with Brendan D. Curti,
M.D., testing pre-operative anti-OX40 immunotherapy plus RFA in
patients with colorectal cancer that has metastasized to the liver.
Dr. Newell’s clinical interests also include pancreatic cancer,
with projects that focus on prognostic approaches to support
informed clinical decision making for these patients. At the 2015
annual meeting of the Society for Immunotherapy of Cancer,
she described an analysis of circulating immune cells as potential
biomarkers for malignancy of pancreatic tumors. She also gave
an oral presentation at the North Pacific Surgical Association
conference on results from a retrospective analysis of the use
of pre-operative CT scans to predict the development of postoperative pancreatic fistula after pancreatectomy, accepted for
publication in the American Journal of Surgery. With the recent
push to use personalized medicine to predict which patients will
benefit from specific therapies, she is collaborating with Rom S.
Leidner, M.D., to perform whole-exome sequencing in patients
with head and neck cancer and pancreatic adenocarcinoma.
Community outreach and collaboration are important to
Dr. Newell. She organizes a Portland city-wide HCC meeting that
brings together specialists from multiple disciplines to discuss
the latest updates on management of hepatocellular carcinoma.
The conference includes providers from many different hospital
systems and private clinics in Portland.
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David B. Page, M.D.
Assistant member, Breast Cancer
Immunotherapy
Medical Oncology
As a newly-appointed faculty
member, Dr. Page seeks to explore
novel combination strategies, identify
immune-based biomarkers of response, and develop
cancer immunotherapies to improve outcomes for
patients with breast cancer.
Dr. David Page joined the Earle A. Chiles Research Institute in
July 2015 after completing a medical oncology fellowship at
Memorial Sloan Kettering Cancer Center. His research focuses
on the clinical development of immunotherapy in breast cancer.
Dr. Page serves the Portland breast cancer advocacy community
as a clinician, researcher, and educator. He is a board member
of the Breast Friends Foundation, Medical Advisory Committee
member for the Ore. and SW Washington Chapter of the Susan
G. Komen Foundation and a frequent peer-reviewer for grant
agencies and academic journals.
“My primary research focus is to develop and implement clinical
trials that evaluate novel combination strategies designed to
overcome immunologic tolerance in breast cancer,” says
Dr. Page. Since his arrival, Dr. Page has developed several
investigator-initiated clinical trials for both early stage breast
cancer and metastatic disease. These include a study combining
cytotoxic chemotherapy with immunologic checkpoint blockade
to characterize the immunologic effects of chemotherapy, a

study to evaluate whether next-generation immune-based
assays, such as T-cell receptor sequencing or RNA transcriptional
profiling, can predict clinical response in early stage breast
cancer, and studies evaluating pre-operative immunotherapy
in early stage breast cancer.
“My secondary focus is to develop novel immune-based
biomarkers that may one day be used to guide treatment
with immunotherapy,” says Dr. Page. “I have expertise in flow
cytometry, seromics, and cytokine array platforms, as well as
next-generation sequencing assays including Nanostring and
T-cell clonal repertoire analysis.” Grant funding from the Terri
Brodeur Breast Cancer Foundation supports Dr. Page’s research
to evaluate clonal repertoire analysis as a novel predictive
biomarker in the setting of neoadjuvant pertuzumab-based
chemotherapy to facilitate disease control in women with brain
metastases. A Carol Litwin Memorial Fellowship from the SASS
Foundation supports his Phase Ib study of peri-operative
cryo-immunotherapy and candidate immune-based predictive
biomarkers to harness the curative potential of lymphocytes in
women with early stage breast cancer.
In 2015, Dr. Page was honored with a Young Investigator Award
from the American Society of Clinical Oncology, one of 58 award
recipients worldwide, to investigate T-cell receptor DNA deep
sequencing as a novel immune-based biomarker in early stage
breast cancer. He also received a Clinical Research Excellence
Award from the Immuno-Oncology Young Investigator’s Forum,
a program of the Academic Research Coalition, and a Breast
Symposium Merit Award from the Society for Immunotherapy
of Cancer.
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William L. Redmond, Ph.D.
Associate member, Cancer
Immunotherapy Laboratory
Dr. Redmond and his laboratory seek
to elucidate the mechanisms by which
T cell co-stimulation through ligation of
the TNF receptor family member OX40
(CD134) boosts CD8 T cell survival, differentiation,
and the efficacy of tumor immunotherapy.
“We are exploring how specific combinations of immunotherapy
agents can be used to boost the function of specialized white
blood cells, known as killer T cells, which have the ability to
detect and eliminate malignant cells,” says Dr. Redmond. “By
understanding the mechanisms by which these drugs regulate
tumor-specific immunity, we hope to develop more effective
cancer therapeutics capable of harnessing the power of the
immune system.”
One area of active investigation is how combinatorial approaches
to immunotherapy can synergize to increase anti-tumor immunity.
These studies helped demonstrate how two different immuneboosting drugs, anti-OX40 antibody plus interleukin-2, could be
combined to induce more robust tumor regression than either
agent alone. Research conducted by Dr. Redmond’s laboratory
has also revealed a unique synergy between OX40-specific

immunotherapy and blockade of the immune checkpoint CTLA-4.
“This approach was the equivalent of stepping on the gas pedal
while taking your foot off the brakes,” said Dr. Redmond.
Another major focus of the laboratory is investigating the
mechanisms by which tumor-specific vaccines plus combination
immunotherapy can revive killer T cells that had been suppressed
by the tumor. “We are studying how dual anti-OX40/anti-CTLA-4
therapy plus vaccination rescues killer T cells that have been shut
down by progressively growing tumors so that they can be
reactivated to destroy the cancer,” says Dr. Redmond.
Key accomplishments in 2015 include receiving a Career Catalyst
Research Grant from the Susan G. Komen Foundation and an R21
grant award from the National Cancer Institute with Brendan D.
Curti, M.D., to fund an on-going phase I clinical trial of Ipilimumab
(anti-CTLA-4) plus a Galectin-3 inhibitor (GR-MD-02) in patients
with metastatic melanoma. Additionally, there were three
publications from Dr. Redmond’s team in 2015, highlighted by a
forthcoming article in Proceedings of the National Academy of
Sciences entitled Combination OX40 Agonism/CTLA-4 Blockade
with HER2 Vaccination Reverses T-cell Anergy and Promotes
Survival in Tumor-Bearing Mice. Four poster presentations were
made by Redmond Laboratory postdoctoral fellows and research
associates at the Society for Immunotherapy of Cancer 2015
annual meeting.
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Rachel E. Sanborn, M.D.
Associate member, Phase I Clinical Trials
Program
Co-director, Providence Thoracic
Oncology Program
Medical Oncology
Dr. Sanborn’s research interests and clinical practice include
clinical and translational research in thoracic oncology, and
the development of new agents via the Phase I Clinical Trials
Program at Providence Cancer Center.
The primary focus of Dr. Rachel Sanborn’s clinical and translational
research involves the investigation of immunotherapy or in
combinations of immunotherapy agents with standard therapy.
“This entails partnering with pharmaceutical companies in novel
clinical trials, as well as partnering with other institutions across
the country in the conduct of research,” says Dr. Sanborn.
“This also includes collaborating with the immunologists at
our institution investigating novel agents, such as the DRibble
vaccine, in ongoing clinical trials, and in the active process of
developing new clinical trials.”
The Phase I Clinical Trials Program has expanded significantly
over the past year, dramatically increasing the number of
available Phase I clinical trials to more than 50 by year-end 2015.
“The reputation of the Earle A. Chiles Research Institute as a
referral center for early-phase and innovative research has
grown commensurately, with a steady increase in referrals from

across the region and out of state,” says Dr. Sanborn.
Dr. Sanborn opened and initiated accrual to an investigatorsponsored Phase I/II trial of MK-3475 with gemcitabine in
patients with previously-treated advanced non-small cell
lung cancer.
In 2015, Dr. Sanborn was elected by colleagues to serve as
medical director for the Cancer Research and Biostatistics (CRAB)
Clinical Trials Consortium Lung Cancer Research team. This
is a four-year term, which will involve working with the
multi-institution consortium in developing and expanding
the clinical research portfolio and memberships.
Dr. Sanborn also served as a peer reviewer for grant applications
for the Department of Defense Lung Cancer Research Program
and as a panel member for the American Lung Association
Take Action Network. She was co-chair of the American Lung
Association’s Lung Force Expo held in Portland, Ore., where she
presented on “Lung cancer screening: Evidence, benefits, and
pitfalls from a high-volume program’s perspective.” She also
serves as a member of Free to Breathe’s Medical Advisory
Workgroup, which consists of a panel of physicians focused
on thoracic oncology nationally.
Within Providence Health & Services, Dr. Sanborn is a member of
the Thoracic Oncology Clinical Focus Group, and acts as co-chair
for its thoracic medical oncology working group subcommittee.
She is also a member of the Genomics Clinical Focus Group.
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Andrew D. Weinberg,
Ph.D.
Member, Basic Immunology Laboratory
Dr. Weinberg and his laboratory focus on
cellular and molecular mechanisms of
action of OX40 agonists. OX40-based
therapy leads to tumor regression in cancer-bearing
mice, both as monotherapy or when combined with
other immunotherapy modalities. Their pre-clinical research
has shown that OX40-based therapy leads to tumor
regression, both as monotherapy and when combined
with other immunotherapy modalities.
The Basic Immunology Laboratory led by Dr. Andrew Weinberg
uses pre-clinical models to study the molecular pathways involved
in co-stimulation of T cells using agonist anti-OX40 antibodies.
“Using an immunization model in the lab, we examined changes
that occur in phospho-protein levels within antigen-stimulated
T cells comparing anti-OX40 to the immune check-point inhibitor
anti-CTLA-4. We found that anti-OX40 treatment led to
increased T cell survival and production of memory T cells,”
says Dr. Weinberg. In the MCA205 pre-clinical tumor model,
anti-OX40 was found to bind to regulatory T cells (Tregs) from
the tumor microenvironment. To characterize how OX40 agonists
affect Treg function, gene array experiments were performed to
analyze the molecular changes of Tregs from tumors treated with
and without anti-OX40. “Several transcripts within tumor-isolated
Tregs were consistently altered with OX40 agonists. We are
currently confirming these changes on the protein level,” says
Dr. Weinberg.
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Dr. Weinberg is engaged in multiple preclinical and clinical
intramural collaborations with the Providence Oral, Head and
Neck Cancer Program, Breast Cancer Program, Radiation
Oncology, and Cytokine and Adoptive Immunotherapy Program,
as evident in his co-authorship of the review article OX40
Signaling in Head and Neck Squamous Cell Carcinoma:
Overcoming Immunosuppression in the Tumor Microenvironment
(Oral Oncology. 2016;52:1; Epub 2015 Nov 21). Examinations
by his laboratory of immune response to combination anti-OX40
and TGFß receptor blockade resulted in a publication for which
he was senior author (Cancer Immunol Res 2015, 3(5):526).
In recognition of his seminal contributions to the emerging field of
T-cell agonist immunotherapy, Dr. Weinberg was selected to serve
as a co-organizer for the Society for Immunotherapy of Cancer
30th Anniversary Annual Meeting held in National Harbor, Md.
He also served as co-chair for the meeting’s Coinhibition and
Costimulation Session which focused on new costimulation
(OX40) and coinhibition (VISTA) pathways of T cells, and
combination therapy with anti-CTLA-4 and anti-PD-1.
Dr. Weinberg also co-chaired the inaugural Cambridge Health
Institute Agonist Immunotherapy Targets stream at the 11th
Annual Protein Engineering Summit held in Boston. He served as a
moderator of the Combinations in Cancer Immunotherapy Session
and also presented on OX40 Agonist Combined with PD-1 and
TGFß Receptor Blockade. Additional speaking invitations brought
Dr. Weinberg to the 8th Annual Canadian Cancer Immunotherapy
Consortium Symposium, the inaugural New Horizons in
Immunotherapy for Head and Neck Cancer Symposium held in
Newberg, Ore., and to South Korea for seminars given to the
Korean Society for Immunology and Academy of Immunology
and Microbiology.
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Kristina H. Young, M.D.,
Ph.D.
Assistant member, Tumor
Microenvironment Laboratory
Radiation Oncology
Dr. Kristina Young joined the faculty of the
Earle A. Chiles Research Institute to pursue translational
cancer immunotherapy research with a focus on the tumor
microenvironment and radiation oncology.
Dr. Kristina Young’s research interests include the role of cancerassociated fibroblasts on immune-mediated radiation resistance in
the treatment of pancreatic cancer. Her laboratory is investigating
how inhibition of the fibroblast activation protein (FAP) combined
with radiation can delay or impede tumor growth. “Thus far
we have found that FAP inhibition with radiation results in two
separate tumor growth delays in pre-clinical models. We observed
an early delay approximately seven days following radiation
therapy, and a second delay approximately three weeks following
last therapy,” says Dr. Young. Additional experiments are planned
to determine the mechanism of action and enhance these
findings. The laboratory is also investigating the direct and
indirect inhibition on radiation efficacy. “Based on our previously
published data demonstrating enhanced radiation efficacy in
pre-clinical models, we are performing further experiments to
determine if the improved response to radiation was a direct
effect of CD8 T cells,” says Dr. Young.

EDUCATION &
TRAINING

EVENTS &
ENGAGEMENT

FRANZ LEADERSHIP
CABINET

SELECT
PUBLICATIONS

Dr. Young is also an active clinical investigator. She is principal
investigator of an investigator-initiated Phase II clinical trial
testing TGFß inhibition in patients undergoing neoadjuvant
chemoradiation for locally advanced rectal cancer, and is
engaged in intramural collaborations with Todd S. Crocenzi,
M.D., and Philippa H. Newell, M.D., on a multi-institution Phase I
trial of stereotactic body radiation therapy (SBRT) plus nivolumab
in patients with hepatocellular carcinoma not eligible for other
liver-directed therapies. Additionally, her collaborations with
Marka R. Crittenden, M.D., Ph.D., and Michael J. Gough, Ph.D.,
resulted in the journal article, Comparing Equals When
Evaluating Immunotherapy with Different Doses and Fractions
of Radiation Therapy (Immunotherapy. 2015;7(8):847).
In 2015, Dr. Young was honored by the American Society for
Clinical Oncology as one of 58 young investigators worldwide
to receive its prestigious Young Investigator Award. The award
will fund her translational research proposal, entitled Targeting
the Tumor Stroma to Enhance Radiation Efficacy, to advance
state-of-the-art cancer immunotherapy through improving the
immune response to cancer among patients receiving radiation
therapy. She was also awarded a Research and Education
Foundation Seed Grant from the Radiologic Society of North
America for her proposal Targeting Cancer-Associated Fibroblasts
to Enhance Radiation Efficacy.
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CORE FACILITIES
The Robert W. Franz Cancer Research Center, founded in
1993 by Walter J. Urba, M.D., Ph.D., and a small team of
scientists, is part of the Earle A. Chiles Research Institute
at Providence Cancer Center.
Research laboratories
of the Earle A. Chiles
Research Institute are
in close proximity to the
oncology clinics and
patient rooms within
Providence Cancer
Center so that scientists
never lose sight of the
people their research
is intended to serve.
This environment
encourages translational research, also known as bench-to-bedside
research, where scientists and physicians partner to translate
the most promising discoveries from the laboratory into novel
treatments for patients in Oregon and throughout the country.

Immune Monitoring Laboratory
Established in 2000, the mission of the Immune Monitoring Laboratory
(IML) is to support clinical investigators and research scientists at
Providence Cancer Center and throughout the United States by
providing real-time, state-of-the-art monitoring of cancer patients’
immune responses during immunotherapy clinical trials. The IML is also
the archival and disbursement center for the acquisition, processing,
cryopreservation and cataloguing of all peripheral blood mononuclear
cells and serum collected during the course of cancer clinical trials.
The IML team is among the nation’s leaders in developing and
implementing immune monitoring assays for the evaluation of
anti-tumor immune responses in cancer patients receiving
immunotherapy. They measure patients’ immune responses
to different anti-cancer immunotherapy interventions, such as
checkpoint inhibitors, T-cell agonists, and experimental cancer
vaccines, to assess their effectiveness. They use a variety of
standardized assays specifically designed and optimized to monitor
changes and detect responses in cancer patients’ immune systems
throughout the course of their treatments.

The Earle A. Chiles Research Institute is home to state-of-the-art
core facilities offering the latest in immunological monitoring,
flow cytometry and molecular pathology and informatics services.
These facilities are available to both intramural and extramural
investigators.

Peripheral Blood Mononuclear Cells (PBMC) and serum (left) are isolated
and stored in liquid nitrogen tanks for use on subsequent assays (right).
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Flow Cytometry Core

Molecular Pathology Core

The IML encompasses the Flow Cytometry Core, a valuable resource
to all intramural investigators. Highly sophisticated polychromatic
flow cytometry techniques allow investigators to measure anti-tumor
immune responses on a cellular level. The results help researchers
refine their studies and improve immunotherapy strategies for
patients at Providence Cancer Center and throughout the world.
The Flow Cytometry Core provides sample processing, staining,
data acquisition and analysis under the supervision of experienced
research personnel who assist in the design and execution of
multi-color flow cytometry and all sorting experiments.

The Molecular Pathology
Laboratory (MPL) is a
fundamental and strong
component of translational
research of the Earle A.
Chiles Research Institute.
The MPL provides translational immunologists with molecular
correlates to their research questions. The MPL leverages
shared clinical infrastructures dedicated to the deployment
of a system-wide personalized medicine program enabling
high-throughput “-omics” projects with clinically validated
bioinformatics pipelines supported by a dedicated in-house
software development team. All applications include data security,
access logs, data storage, and backup and are built to operate in
the clinical setting.

The Flow Cytometry Core is equipped with a BD LSRII, BD FACS
Aria II Cell Sorter with BSL2 Containment System, BD FACS Calibur,
CTL ImmunoSpot ELISpot, Bio-Plex 100 and Guava PCA-96,
among other state-of-the-art immunological monitoring and
flow cytometry resources.

Fresh blood is stained with approximately 70 antibodies (left); the
stained cells are then measured with a flow cytometer (right).

The MPL is part of Providence Health
and Services laboratories, licensed by
the Oregon State Health Division and
accredited by various agencies such as
the College of American Pathologists,
Joint Commission, Accreditation of
Hospitals Organization, American
Association of Blood Banks and FDA.
The MPL maintains a significant and
diverse sequencing infrastructure
including the latest Illumina and Ion
Torrent instrumentation as well as instruments for performing
Sanger sequencing and quantitative polymerase chain reaction
(PCR). The large-capacity HiSeq 2500 is devoted to exome
sequencing, RNA-seq and other genomics applications.
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EDUCATION & TRAINING
GRADUATE EDUCATION

POSTDOCTORAL FELLOWSHIPS

Since 1994, the Earle
A. Chiles Research Institute
has trained the next
generation of tumor
immunologists.

Earle A. Chiles Research Institute provides a rich
postdoctoral training environment that stimulates
creativity and nurtures professionalism for fellows
pursuing careers in cancer immunotherapy.

Through a partnership with
Oregon Health & Science
University School of Medicine,
graduate students conduct
research under the mentorship of a faculty member with a joint
appointment at the School of Medicine and the Earle A. Chiles
Research Institute. Students accepted into doctoral programs in
Molecular Microbiology and Immunology, Molecular and Cellular
Biosciences, and Cancer Biology attend university courses and
conduct research at the Earle A. Chiles Research Institute in the
laboratory of their faculty advisor. Students have the opportunity to
give poster presentations at national conferences and present their
research at department seminars while advancing to doctoral
candidacy. Faculty advisors serve as members of the students’
thesis committees, guiding them through thesis defense to degree
completion. Upon receipt of their doctoral degrees, previous
students have been accepted to postdoctoral fellowships at the
National Cancer Institute, INSERM (French National Institute of
Health and Medical Research) and within the biotechnology industry.

Postdoctoral fellowships serve as training periods of scholarly,
mentored research for doctoral degree holders seeking to acquire
the professional skills and experience necessary for independent
scientific careers. With input and guidance from their faculty
mentors at the Earle A. Chiles Research Institute, fellows develop
individualized development plans to identify professional
development opportunities and career objectives which serve to
guide them through their fellowships.
In addition to discipline-specific
expertise, conceptual knowledge and
research skill development, fellows
are also mentored in leadership,
management, communication, and
the responsible conduct of research.
Fellows are encouraged to obtain
external funding and develop a strong
publication record to provide a solid
foundation for transitioning to an
independent scientific career. Previous postdoctoral fellows have
received funding from the NIH Pathway to Independence Award
(K99), American Cancer Society Postdoctoral Fellowship Award,
and Prostate Cancer Foundation Young Investigator Award, and
obtained appointments at Rush University, Oregon Health & Science
University, Legacy Research Institute and the Earle A. Chiles Research
Institute upon completion of their training fellowships.
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SUMMER RESEARCH PROGRAM
The Earle A. Chiles Research Institute offers a summer
research program for undergraduate students pursuing
a career in biomedical sciences.
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Research projects and poster presentations from the
2015 cohort include:
• Sting Ligand and its Effect on SOCS Production
• Soluble Intercellular Signaling Factors in the
		 Tumor Microenvironment
• Different Therapeutic Anti-PD-1 Clones Prevent or
		 Allow the Detection of PD-1 via Flow Cytometry
• Cross Presentation of DRibble Vaccine Independent
		 of MyD88 Adaptor Protein
• OX40 Immunotherapy Effect on Tumor Resident Regulatory
		 T cell Function and Phenotype

The intensive nine-week internship is designed to provide direct,
hands-on research experience and mentorship for undergraduate
students who are interested in biomedical research. Under the
guidance of a faculty mentor, interns complete an independent
research project and present their findings at a capstone poster
session. Interns also attend regular bioinformatics classes,
institute-wide research seminars, and Journal Club meetings.

Past interns have been
accepted to Oregon
Health & Science
University School of
Medicine, Northwestern
University School of
Medicine, and The Mayo
Clinic Graduate School.

2015 Summer Research Program Cohort
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EVENTS & ENGAGEMENT
CREATING HOPE LUNCHEON
2015 marked the 17th anniversary of the Creating Hope
for Cancer Patients Luncheon, the signature fundraising
event of Providence Cancer Center benefitting the
Earle A. Chiles Research Institute.
With more than 540 guests in attendance and a $100,000
matching challenge, the 17th Annual Creating Hope Luncheon
garnered a record-breaking $620,000 in contributions. Emceed
by Matt Zaffino of KGW Channel 8 News, the program included
remarks from cancer patients and survivors, including a keynote

2015 Creating Hope Luncheon speakers (L to R): Mark Williams,
Luncheon co-chair and cancer survivor; Nick Morris, Ph.D., Weinberg
Lab scientist and cancer survivor; Marisa Acocella Marchetto, keynote
speaker; Walter J. Urba, M.D., Ph.D., director, Earle A. Chiles Research
Institute; Julie Randall, cancer patient with husband Scott; and
Michelle Judson, cancer survivor with daughter Scarlett.

address from cancer survivor, cartoonist and author of Cancer
Vixen, Marisa Acocella Marchetto. Survivors shared stories of their
treatment and care at Providence Cancer Center and inspired
hope in others. Walter J. Urba, M.D., Ph.D., director of cancer
research at the Earle A. Chiles Research Institute, was joined by
Nick Morris, Ph.D., cancer survivor and senior research scientist,
in conveying the importance of philanthropy in advancing cancer
research and immunotherapy.

FINISH CANCER CAMPAIGN
The 2015 Creating Hope
Luncheon served as the
launch of Providence Cancer
Center’s award-winning
#FINISHCANCER campaign.
Honored with a 2015 Gold
Award by the Cancer Awareness
Advertising Awards Program, the
#FINISHCANCER campaign aims to
raise awareness of recent advancements in cancer research –
namely immunotherapy – and the need for continued funding.
The campaign emphasizes the “I CAN” in “FINISHCANCER,”
calling on all to help finish the fight against cancer. Whether
through volunteering, advocacy, donations or promoting cancer
screenings and prevention, all have a role to play in finishing
cancer. Visit www.finishcancer.org to learn more.
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PROVIDENCE HOOD-TO-COAST RELAY

WHITE OUT CANCER DAY

More than $565,000 was raised for cancer research
at Providence Cancer Center by participants and
supporters of the 2015 Hood-To-Coast Relay.

A day devoted to raising awareness of cancer
immunotherapy, the Earle A. Chiles Research Institute
joined institutions across the world in celebrating
#WhiteOutCancerDay.

For the second year in
a row, Providence Health
& Services was the title
sponsor of the world’s
largest relay race,
Providence Hood-ToCoast Relay, spanning
198 miles from Timberline
Lodge on Mt. Hood to
the coastal town of
Runners For Research Van 1 at Timberline
Seaside, Ore. Considered Lodge.
the “mother of all
relays,” this two-day event included 12,600 runners comprising
1,050 teams supported by 3,600 volunteers.
Several teams from Providence Health & Services competed,
including Providence Cancer Center team “Runners For Research”
led by team captain Samantha Kaiser, director of cancer research
operations at the Earle A. Chiles
Research Institute. Fellow
teammates included researchers,
administrators, providers,
advocates, patients and
Providence Oregon CEO,
Dave Underriner.
Runners For Research Van 2 at
Providence Cancer Center.

On June 12, 2015, Providence researchers stood side by side
with oncologists, nurses, fundraising officers, administrators and
support staff to show support for cancer immunotherapy, shared
via Providence Cancer Center social media using hashtags
#WhiteOutCancer and #FinishCancer.

Researchers, clinicians, advocates, administrators and support staff wear
white in support of #WhiteOutCancerDay.
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FRANZ LEADERSHIP CABINET
The Robert W. Franz Leadership Cabinet comprises
men and women with a strong desire to connect our
local community with dedicated teams of researchers
at the Earle A. Chiles Research Institute working to
finish cancer.
Founded in 2001, the leadership cabinet has a strong and loyal
membership representing a broad spectrum of the community.

2015 CABINET MEMBERS
Charlie Engleberg, Chair

Tyler Johnson

Flo Atkinson

Sheryl Langerman Rosenfeld

Stephen Bader, M.D.

Lynn Loacker

Mark Beckius

TJ O’Connor

Walter Bowen

Linda Read

Earle M. Chiles

James F. Robb, Ph.D.

Maxine Cracraft

Linda Smiley

Dan Floyd

Jim Snow

Robert W. Franz

Judi Swift

Diana Hall

Mark Williams

Cindy Harder

Linda Yoshida

At the Earle A. Chiles Research Institute,
scientists work in lockstep with physicians
to discover ways to harness our own immune
systems in the fight against cancer. “I continue
to be amazed by the number of times
researchers at the Earle A. Chiles Institute
have been first in Oregon, first in the country,
even first in the world, to deliver novel
treatments to patients,” says Charlie
Engleberg. “Cancer immunotherapy is
proving to save lives!”

2015 Franz Leadership Cabinet with ex-officio members Bernard A. Fox,
Ph.D., and Walter J. Urba, M.D., Ph.D., pictured second row far left and
far right, respectively. Not all members pictured.
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